Mothers with obesity at greater risk of stillbirth: Canadian study – National

Mothers with obesity at greater risk of stillbirth: Canadian study – National

With obesity rates rising in Canada and globally, new research suggests there is a higher risk of stillbirth in mothers with obesity. Experts say early delivery could help minimize those risks. The study published in the Canadian Medical Association Journal (CMAJ) Monday found that maternal obesity on its own and along with other risk factors, … Read more

More than 1B people live with obesity globally, study shows. What about Canada?  – National

More than 1B people live with obesity globally, study shows. What about Canada?  – National

More than one billion people worldwide are grappling with obesity, with children in particular experiencing alarming increases in numbers, a new study shows. A global analysis published in the Lancet on Thursday found that obesity rates in children and adolescents across the world surged fourfold from 1990 to 2022. During this period, obesity rates more … Read more

The big decisions you’ll need to make once on new weight loss drugs

The big decisions you’ll need to make once on new weight loss drugs

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.  Brendan Mcdermid | Reuters For all of the promise associated with new weight loss drugs such as Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound in treating obesity, there’s a very big risk printed right on … Read more

What you need to know about health coverage for new weight loss drugs

The big decisions you’ll need to make once on new weight loss drugs

Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to … Read more

Nvidia rally fueling FOMO in overall market: Evercore’s Julian Emanuel

Nvidia rally fueling FOMO in overall market: Evercore’s Julian Emanuel

Evercore ISI’s Julian Emanuel thinks Nvidia’s monster rally is fueling a fear of missing out in the market. He finds clients, including many who traded through the dot-com boom and subsequent collapse, are more worried about being underinvested than overexposed right now. “That’s the first time that’s happened since 2021 for us,” the firm’s senior … Read more

Drugs like Ozempic and Wegovy show no link with suicide, FDA says

Drugs like Ozempic and Wegovy show no link with suicide, FDA says

A preliminary review of side effects from popular drugs used to treat diabetes and obesity shows no link with suicidal thoughts or actions, the U.S. Food and Drug Administration said Thursday. But the agency also said officials cannot definitively rule out that “a small risk may exist” and that they’ll continue to look into reports … Read more

Feelings of depression linked to short-term weight gain, study finds – National

Feelings of depression linked to short-term weight gain, study finds – National

As the winter blues set in for many in Canada, experts say feelings of depression can lead people to gain weight, with new research suggesting that the risk of weight increases in the short term are higher in people who are already obese. A study by University of Cambridge scientists published in the PLOS ONE … Read more

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound. The drugmaker said Thursday it will use the site, called LillyDirect, to pair visitors with third-party mail-order pharmacies for prescriptions and to care providers through a virtual medical weight-loss clinic. The site … Read more

New weight loss drugs are out of reach for millions of older Americans because Medicare won’t pay

New weight loss drugs are out of reach for millions of older Americans because Medicare won’t pay

WASHINGTON — New obesity drugs are showing promising results in helping some people shed pounds but the injections will remain out of reach for millions of older Americans because Medicare is forbidden to cover such medications. Drugmakers and a wide-ranging and growing bipartisan coalition of lawmakers are gearing up to push for that to change … Read more